Highlights vom ERA 2025 in Wien

Dr. Marcus Säemann präsentiert seine Highlights vom ERA 2025 in Wien.Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabeteshttps://www.nejm.org/doi/abs/10.1056/NEJMoa2410659Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabeteshttps://www.nejm.org/doi/full/10.1056/NEJMoa2501006ARO-C3, an investigational RNAi Therapeutic Targeting Complement C3, Reduces Proteinuria, Hematuria, andComplement Activity in IgAN Patientshttps://ir.arrowheadpharma.com/static-files/71ace783-f6cd-47ac-b9a5-5809c13b70f1Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacyhttps://sciencelibrary.sobi.com/sites/default/files/documents/Fakhouri_VALIANT_52w_ERA2025_Oral.pdfImpact of acute eGFR dips and markers of disease severity on effects of empagliflozin on acute kidney outcomehttps://era-apps.m-anage.com/era25/en-GB/pag/presentation/505078#xd_co_f=NGQ1M2RkMjgtOTdjOC00NjgwLTk4NjQtZjJmZTUxYmJkNTcw~https://www.youtube.com/watch?v=bX2Xtj_8mkghttps://www.renalandurologynews.com/reports/egfr-dip-empagliflozin-initiation-acute-renal-risks-treatment/#:~:text=Dr%20Staplin's%20team%20concluded%2C%20%E2%80%9CEmpagliflozin,of%20these%20diseases'%20severity.%E2%80%9DDieser Podcast wurde mit freundlicher Unterstützung von Boehringer Ingelheim RCV GmbH & Co realisiert.Support the show